Back
Full-text
Journal article

Hypertrophic obstructive cardiomyopathy: what, when, why, for whom?

  • Mestres CA Department of Cardiovascular Surgery, Herzzentrum University Hospital Zürich, Zürich, Switzerland.
  • Bartel T Department of Cardiology, Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
  • Sorgente A Department of Cardiology, Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
  • Müller S Department of Internal Medicine, Cardiology, Tirol Kliniken, University of Innsbruck, Innsbruck, Austria.
  • Gruner C Department of Cardiology, Herzzentrum University Hospital Zürich, Zürich, Switzerland.
  • Dearani J Department of Cardiovascular Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
  • Quintana E Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Show more…
  • 2018-02-14
Published in:
  • European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. - 2018
Cardiac Surgical Procedures
Cardiomyopathy, Hypertrophic
Heart Septum
Humans
Treatment Outcome
English Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder and is associated with symptoms of heart failure and increased risk of sudden cardiac death. The most common condition is obstruction of the left ventricular outflow tract. Surgical septal myectomy and alcohol septal ablation are the 2 accepted modes of septal reduction therapy and are indicated when there are advanced symptoms and a peak left ventricular outflow gradient ≥50 mmHg. Advantages of alcohol septal ablation are limited groin approach, reduction of obstruction of the left ventricular outflow tract and functional improvement, but there are higher chances for intracardiac device implantation and residual obstruction. Septal myectomy offers very low mortality, absolute and immediate resolution of obstruction of the left ventricular outflow tract and survival comparative to a matched general population with almost negligible residual obstruction. It is recommended that patients with obstructive hypertrophic cardiomyopathy should be treated at experienced centres.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/24154
Statistics
Document views: 16 File downloads:
  • fulltext.pdf: 0